Boston Scientific — Financial Results

Revenue Growth Remains Exceptionally Strong, Driven by the Cardiovascular Division

Boston Scientific has grown revenue by nearly 41% over just two years, reaching $20 billion in 2025. Even stripping out acquisitions and currency moves, organic growth (the underlying business, apples-to-apples) ran at 15.8% — well above the pace of a typical medical device company. The Cardiovascular division led the way with 20.8% organic growth, while every other division also posted solid gains.

Farapulse Is the Standout Product Powering the Growth Story

The Farapulse Pulsed Field Ablation (PFA) System — a device that treats abnormal heart rhythms by destroying targeted heart tissue using electrical pulses rather than heat or cold — launched in the U.S. in early 2024 and has been the single biggest driver of the company's recent performance. The Cardiovascular division, where Farapulse lives, grew from $8.8 billion to $13.3 billion in two years. The success of Farapulse also came at a cost: it cannibalized Boston Scientific's own older cryoablation (freezing-based) technology, resulting in inventory write-offs and an $386 million impairment charge in 2024 on those older assets — though that charge dropped sharply to $46 million in 2025 as the transition largely played out.

Profitability Improved Substantially, With Net Income Up 56%

The gap between reported and adjusted net income (which strips out one-time items like restructuring costs and amortization) is wide, so both figures are worth noting. The adjusted figure growing 23% is a cleaner read on operating momentum. Gross margin (the percentage of revenue left after production costs) nudged up to 69%, helped by a richer product mix, though tariffs and charges from the ACURATE valve exit partially offset the gains.

Boston Scientific Killed Its ACURATE Heart Valve Program

In mid-2025, the company discontinued worldwide sales of the ACURATE neo2 and ACURATE Prime Aortic Valve Systems — devices used to treat narrowed heart valves — and abandoned its pursuit of FDA approval. The decision triggered roughly $87 million in restructuring charges. This is a meaningful strategic retreat from one product area, but the company framed it as a reallocation of resources toward the rest of its portfolio, which is clearly performing well.

A $14.5 Billion Acquisition of Penumbra Would Be Transformational

After the year ended, Boston Scientific announced a deal to acquire Penumbra — a publicly traded company focused on removing blood clots from blood vessels — for approximately $14.5 billion. This would be a very large transaction for a company currently carrying $11.4 billion in total debt. The plan is to fund roughly $11 billion through new debt and cash, with the rest paid in company stock. Investors should watch this closely: it would significantly increase the company's debt load and dilute existing shareholders, though it would also meaningfully expand the Cardiovascular division's reach.

R&D Spending Is Accelerating

Research and development spending jumped 27% in 2025 to $2.05 billion, and ticked back up as a share of revenue. This signals the company is investing heavily to maintain its innovation pipeline — including bringing newly acquired technologies through clinical trials and toward regulatory approval — rather than coasting on Farapulse's success.

Tariffs and Macroeconomic Uncertainty Are a Real, Unquantified Risk

Management flagged tariffs as a specific and ongoing concern, noting they already impacted gross margins in 2025 and could worsen. The company manufactures and sells globally, making it exposed to both U.S. tariffs on imports and potential retaliatory tariffs from countries like China on U.S.-made products. Management acknowledged there is no guarantee they can fully offset these costs, and the ultimate impact depends on how trade policy evolves — something outside their control.